Today: 19 May 2026
Browse Category

XETRA:MRK 27 June 2025 - 9 January 2026

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Immunome shares rose 7.4% to $21.97 Friday after recent Phase 3 data showed its lead drug varegacestat cut disease progression or death by 84% in desmoid tumor patients. The company plans to file for FDA approval in Q2 2026. Immunome also granted stock options to three new hires and will present at the J.P. Morgan Healthcare Conference on Jan. 14.
9 January 2026
···
$100 B Bank Fraud Scandal Triggers Global Market Rout – DAX Sinks Below 24,000 Amid ‘Cockroach’ Fears

German Stock Market Today, 13 Nov 2025: DAX Closes 1.39% Lower at 24,041 as Siemens Slumps; Merck Rises, Allianz Lifts Guidance

Germany’s DAX fell 1.39% to 24,041.62 on Thursday, its steepest drop since October 2025, after Siemens shares plunged 9.4% on weaker-than-expected earnings and plans to spin off most of its Healthineers stake. The broader STOXX 600 closed down 0.6%. Merck KGaA and Renk rose, while Deutsche Telekom and BASF posted corporate updates. Investors shifted focus to upcoming U.S. economic data.
13 November 2025
·····
Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

Biotech Breakthroughs, Pharma Shakeups & Health Alerts – Global News Roundup (Aug 19–20, 2025)

CSL will cut up to 15% of its workforce and spin off its vaccine unit, targeting $500–550 million in annual savings. Medtronic agreed to add two board members and form new committees after Elliott Investment Management took a major stake. Merck KGaA and Skyhawk Therapeutics announced a neurological drug pact worth up to $2 billion. Pfizer, Bristol Myers Squibb, and Regeneron reported improved Q2 2025 earnings.
20 August 2025
·····
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.
27 June 2025
···········

Stock Market Today

  • Kinross Gold Stock Up 96% in One Year: Is It Still a Buy?
    May 19, 2026, 5:12 AM EDT. Kinross Gold (TSX:K) surged 96.4% over the past year but dipped 18.5% last month, closing at C$39.03. Despite this strong rally, a Discounted Cash Flow (DCF) analysis values the stock at C$47.53, implying it is trading at a 17.9% discount and could be undervalued. The DCF method projects future cash flows based on analyst estimates to determine intrinsic value. Kinross Gold's current price-to-earnings (P/E) ratio stands at 11.84, reflecting market sentiment on its profitability and risk. Analysts forecast steady free cash flow through 2030, supporting the bullish valuation. Investors reassessing commodity stocks might find Kinross Gold attractive despite recent volatility, as its fundamentals suggest continued value potential.

Latest articles

Evolution Stock Is Jumping—The €2 Billion Reason Investors Are Watching

Evolution Stock Is Jumping—The €2 Billion Reason Investors Are Watching

19 May 2026
Stockholm, May 19, 2026, 11:01 (CEST) Evolution AB shares jumped in Stockholm on Tuesday after the online casino technology group announced a €2 billion share buyback, giving investors a large and immediate capital-return story after months of concern over regulation and slowing European growth. The stock traded at 723.80 Swedish crowns at 10:51 a.m. local time, up 9.07%, after touching 746.60 crowns earlier in the session, according to Google Finance data. Evolution said late Monday that its board had resolved to start the buyback immediately. (Google) This matters now because the buyback, where a company purchases its own shares and
NextEra shares dip after $66.8B Dominion deal—What’s on traders’ radar now

NextEra shares dip after $66.8B Dominion deal—What’s on traders’ radar now

19 May 2026
NextEra Energy shares fell 4.6% to $89.04 late Monday after announcing a $66.8 billion stock-led merger with Dominion Energy, whose shares rose 9.4% to $67.56. The deal would create one of the world’s largest electric utilities, serving about 10 million customer accounts and owning 110 gigawatts of generation across four states.
Costco Stock Just Hit a High—Here’s the Next Thing Traders Are Watching

Costco Stock Just Hit a High—Here’s the Next Thing Traders Are Watching

19 May 2026
Costco shares closed Monday up 2.62% at $1,076.47, marking a fifth straight gain and outpacing Walmart and Target. April net sales rose 13% to $23.92 billion, with comparable sales up 11.6%. The company will report fiscal third-quarter earnings on May 28. Analysts’ average price target is $1,072.91, just below Monday’s close.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop